Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction

The Washington University

Status and phase

Terminated

Phase 4

Conditions

Mammaplasty

Treatments

Drug: Liposomal bupivacaine

Drug: Bupivicaine HCL

Study type

Interventional

Funder types

Other

Identifiers

NCT02662036

201601064

Details and patient eligibility

About

This study will evaluate the efficacy of analgesia provided by liposomal bupivacaine (Exparel) when compared to bupivacaine HCL as a transverse abdominis plane (TAP) block in terms of discharge milestones, opioid use, costs, and patient-reported satisfaction at 12, 24, and 72 hours. The investigators propose that Exparel will lower opioid use, length of stay, and overall cost of abdominally-based autologous breast reconstruction, and will lead to greater patient satisfaction.

Enrollment

70 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Scheduled for abdominal-based autologous breast reconstruction (DIEP, MS-TRAM, or TRAM).
At least 18 years of age.
Female.
Able to understand and willing to sign a written informed consent document.

Exclusion criteria

Cognitive impairment.
History of abdominal surgery precluding free flap donor site.
Allergy or intolerance to bupivacaine or "amide" anesthetics.
Significant preoperative chronic pain (requiring daily narcotics) or neuropathic pain (requiring daily use of pregabalin or gabapentin) within the previous 3 months.
Pregnant or breastfeeding.